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Abstract 
Background: In medical publications, effectiveness of health interventions for chronic 
diseases is usually expressed as absolute risk reduction (ARR), number-needed-to-treat 
(NNT) or relative risk reduction (RRR). These measures are estimated at one point in time 
and require the hazard rates to be constant over time in order to yield information that is 
representative for the whole interventions period. Measurement at one point in time may not 
be adequate if the relative hazard for the event of interest (typically death) varies with time.  
Individual patient data are required to estimate hazard rates and relative hazards. However, 
survival curves may be used to make inferences about relative hazards.  Crossings and/or 
convergences of survival curves after they have diverged clearly indicates the relative hazard 
is not constant.  
Objectives: To explore how frequent survival curves do converge and/or cross in medical 
research and to investigate determinants of convergences and crossings. 
Design: Review of all publications that included survival graph during 2007 in five major 
peer-reviewed medical journals. The following data were extracted: type of disease, type of 
exposure, number of comparator groups, number of pairwise comparisons, type of primary 
and secondary end-points, sample size, maximum follow-up time, survival curve 
convergences, survival curve crossings, type of epidemiologic study design, result of log-rank 
test (if reported), and country in which the study was undertaken. 
Sample: 177 publications from Annals of Internal Medicine (AIM), British Medical Journal 
(BMJ), Journal of the American Medical Association (JAMA), New England Journal of 
Medicine (NEJM) and The Lancet. 
Results: 78% of the publications had survival curve convergences and 42% survival curve 
crossings. The proportion of survival curve convergences and crossings varied across disease 
type, intervention type, number of comparator groups, number of pairwise comparisons, types 
of primary and secondary endpoints, sample size, study design and length of follow-up time. 
In multivariate logistic regression, survival curve convergence was positively associated with 
„more than one pairwise comparison‟ (OR 3.7, 95% CI 1.3-10.8) and „death as a secondary 
endpoint‟ (OR 8.1, 95% CI 1.1-65.5). No association was found between survival curve 
crossings and any of the explanatory variables.  
Conclusion: Survival curve convergences and crossings are common phenomena in medical 
research. The phenomena seem not to be associated with particular study characteristics. The 
results warrant care in making inferences about the effectiveness of interventions for chronic 
diseases on the basis of measurement at a single point in time.      
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1. Background 
Non-communicable diseases (NCDs) are the leading causes of death and disability 
globally.  In 2002, for example, the four major diseases; cardiovascular diseases (CVD), 
cancer, diabetes, and chronic respiratory illnesses together accounted for 29 million deaths 
worldwide (Yach et al, 2004). The global burden of NCDs is expected to increase in the 
future partly due to the decline in mortality from communicable diseases and partly due to the 
increase in the proportion of the aging population in middle and low-income countries (Alwan 
et al, 2001). In Europe, NCDs accounted for 86% of all deaths. Cardiovascular disease (52%), 
cancer (19%), chronic respiratory disease (4%), diabetes (2%), and other chronic diseases 
(9%) were the major causes of deaths (WHO, 2005). 
In order to tackle the problem, countries have taken a number of preventive and 
curative steps in the form of adoption of multilateral strategies (where WHO plays a leading 
role), national policy directives, and clinical and community levels of interventions. Equally 
important steps have been to measure the benefits of interventions (intervention 
effectiveness).  This is important for at least two reasons. First, in a clinical setting, measures 
of intervention effectiveness provide clinicians with useful information on whether or not a 
given intervention is effective. Second, in managerial settings, measures of intervention 
effectiveness are important to ascertain whether or not a given intervention is cost-effective. 
There are various ways of measuring health interventions effectiveness. One widely used 
measure is gain in survival time (life years) which is usually estimated from survival curves. 
Researchers make use of survival curves to estimate the life year gain of a new treatment 
compared to its comparator (either a placebo or a conventional treatment). They also use 
survival curves to predict how long time members of a given intervention group are expected 
to survive. Moreover, survival curves are an integral part of cost-effectiveness analyses that 
are used for resource allocation and priority setting in health care.   
What actually prompted this very study is that, in medical publications effectiveness 
of health interventions for chronic diseases are usually expressed as absolute risk reduction 
(ARR), number-needed-to-treat (NNT) or relative risk reduction (RRR). These measures are 
estimated at one point in time and require the hazard rates to be constant over time in order to 
yield information that is representative for the whole interventions period. The potential 
danger of such estimate is the tendency to aggregate the effect of treatment as an average 
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benefit, disregarding the possible variation over time. Interventions effectiveness measures 
based on a single point in time may be inadequate if the relative hazard for diverse event 
(typically death) varies with time. While it requires individual patients‟ data to judge how 
much the relative hazard varies over time, such variation can be inferred to exist from the 
survival curves that converge and/or cross. The purpose of this study was to investigate how 
often survival curves do converge and/or cross and explore the main determinants. The 
following section deals with concept of survival analysis followed by the objectives of the 
study. The third section presents the methods and material used in the study. The fourth 
section presents the results of the study, and the final section deals with discussion and 
conclusions. 
2.  Theory and Concept 
2.1 What is survival analysis? 
Survival analysis is a statistical method for analysing survival data that arise 
frequently in the medical setting from both clinical randomized controlled trail (RCT) and 
epidemiological studies. Survival analysis is appropriate when the interest is, for example, to 
study the time duration from a well-defined origin, such as initiation of a treatment or the 
diagnosis of a disease, until the incidence of some particular event of interest, such as death or 
recovery. Although there is usually a clearly defined endpoint of interest, the origin may not 
be well-defined. For example, if it simply refers to time of entry, which may be a rather 
arbitrary feature of the study design, i.e. an extended period of patient recruitment (Figure 1). 
However, it is important to realize that although patients may be recruited at different times, 
the survival curve should represent the experience of each patient from the time of exposure 
(intervention, treatment, risk factor etc). The survival technique enables researchers to follow 
subjects over time and observe the event of interest (as in A, C, and D in Figure 1).  However, 
the event of interest may not be observed in all subjects. Some subjects may withdraw before 
the event of interest was observed (E) or the study was completed before the event of interest 
had been observed (B). In either case, a complete survival time is not available. Thus, survival 
data with such incomplete observation are said to be right censored. All that is known about a 
censored observation is partial information collected up to the point in which the subjects 
were part of the study, i.e. while we do not know the exact time the event occurs for the 
individual, we do know it exceeds the time of censoring (Altman, 1991, Parmar and Machin, 
1996). 
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 Figure 1. Different entry point and subject experience in a typical survival analysis: A, C, &D are fully 
observed; B & E are right censored. E due to drop-out before end of study. (Adapted with modification from 
Altman.1991).  
Survival data collected in such a way (as depicted in Figure 1) are used to estimate survival 
probabilities, to compare survival experiences in different groups, and to assess the 
relationship between explanatory variables and survival time. Such analysis is done through 
the use of survival curves or life tables, as well as dedicated regression techniques.  
2.2 What is a survival curve? 
A survival curve depicts survival probability. The theoretical bases of a survival graph 
are survivor function S(t) and hazard function h(t) (Altman, 1991). Survivor function S(t) 
expresses the probability that an individual will survive up to and including time t.  
S (t) = P (T>t) 
Where, t is a given point in time, T is a random variable denoting the time of an event, and P 
is probability. Put it differently, the formula implies that the survival function is the 
probability that the time of an event such as death occurs later than some specified time. The 
hazard function h(t) expresses the probability that an individual experiences the event 
instantaneously after a time t given the subject has not yet experienced the event. It can 
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increase, decrease, or remain constant over time. A higher hazard rate is associated with lower 
survival (Kirkwood & Jonathan, 2003). 
The survival curve starts at 100% where all subjects are alive and declines with each 
event until the last event of interest or outcome has been observed (Figure 2). When it is 
estimated with the Kaplan-Meier technique, it is a step function in which the survival 
probabilities remain unchanged up to the time of the first event, such as year 1, and followed 
by a step down for each event up until year 6, beyond which the survival probabilities were 
unchanged up to year 12 (this is because no event was observed from year 6 until year 12). 
Effectively, we can not measure any survival time beyond year 12, as this is the end of the 
trial. The area under the curve represents the average survival time.  
 
Figure 2. Graphic illustration of a survival curve. Adapted from Cancer guide homepage 
(http://www.cancerguide.org) 
Depending on the data available survival curves can be estimated using either an 
actuarial method or the Kaplan-Meier method.  In the actuarial method, the x-axis is divided 
into regular intervals, and percent survival is calculated for each interval, as is done in the life 
table method, on the assumption that individuals are lost to follow-up halfway through the 
interval. In the Kaplan-Meier method, the survival probabilities are recalculated each time a 
patient has an event, whereas censorings only remove individuals from the risk set used to 
calculate probabilities at subsequent event times (Wilson, 2004; Altman 1991; Kirkwood & 
Jonathan 2003; Parmer & Mahin, 1995). 
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2.3 Comparing two survival curves 
One of the major purposes of survival analysis is to compare the survival experiences 
of two or more groups. In clinical trials, it is widely employed to compare the result of two or 
more interventions to decide which treatment is more effective. By studying two survival 
curves, researchers analyse whether the survival time is the same or different in two groups 
(Figure3). For example, the group under Treatment A enjoyed a higher median survival time 
(4.4 years) than the group under Treatment B (2.5 years). This means that Treatment A 
provided a gain of almost two life years in terms of median survival time. Similarly survival 
curves can be compared at any other percentile. It is also possible to conclude that patients 
under treatment B have worse survival than those under treatment A throughout the study 
period. This is evidenced from the pattern of the survival graph that the survival curve 
depicting Treatment A lies above the curve depicting Treatment B throughout the follow-up 
period. Studying the figure also roughly informs us whether or not the relative hazard varies 
over the course of the follow-up period. If two survival curves do converge or cross each 
other as in Figure 4, the relative hazard is not constant over time. Even if survival curves do 
not converge or cross each other, the relative hazard may not be constant, but if they converge 
or cross we know for sure that the relative hazard is not constant. Finally, it should be noticed 
that all survival curves by definition coincide at time zero and when all have experienced the 
event. When we refer to convergences and/crossings we, thus, referring to time point in-
between, i.e. when some, but not all subjects experienced the event.   
The question is, however, how to measure effectiveness of an intervention along a 
survival curve. Effectiveness of intervention particularly for chronic diseases can be measured 
horizontally, vertically, or through a combination (Kristiansen and Gyrd-Hansen, 2006, P 
674). By horizontal measure, we mean that by drawing a horizontal line that connects the two 
survival curves (Figure 3), it is possible to capture the percentage of patients alive for some 
particular time period. Although the horizontal effectiveness measure is conventionally 
expressed as median survival (the survival of 50% of the population in each group) as in our 
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example above, it is possible to measure at any survival proportion of the population. 
 
Figure 3. Comparison of two survival curves. Adapted from the Cancer Gide webpage 
(http://www.cancerguide.org) 
For vertical effectiveness measures we draw a vertical line between two survival curves, and 
register the proportion of patients who have experienced the event of interest, such as death. 
And the relation between the survival in the two groups can be expressed in terms of relative 
risk (RR), absolute risk reduction (ARR), number-needed-to treat (NNT) or odds ratio (OR). 
These measures can be taken at any point along a survival curve though usually they are taken 
at the end of the trial. The third way of measuring the outcome of the intervention is by 
measuring the area between the two survival curves. This measure combines both the 
horizontal and the vertical measures, and intends to capture all the information on the 
difference between the two survival curves. It is generally referred as the average 
postponement of an adverse event.  
 
Figure 4 Illustration of survival curve convergences and crossings. Adapted from (Kristiansen and Gyrd-Hansen 
2006). 
However, comparison between groups may be inaccurate and difficult to interpret. Some of 
the reasons for this: 
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The difficulty in singling out whether or not the difference between two groups is due to 
treatment differences rather than patient differences; 2) different types of measures capture 
different aspects of the health effect; 3) Logrank tests are used when they are inappropriate, 
for example, when survival curve cross; and 4) the values of effect measure are highly 
dependent on when they are measured.  
Most health effects are measured at the end of the trial or at some other single arbitrary 
time point. However, such a measure may not provide a relevant comparison of the total 
survival experience between groups, in particular, when it fails to capture: 1) the difference in 
survival across time, and 2) survival curves that may converge or crossover. The purpose of 
our study was, therefore, to investigate survival curve convergences and crossings in medical 
research. To the best of our knowledge no many studies have explored how often survival 
curves do converge or cross and its determinants. Our aim was to capture survival graphs 
from scientific publications presented in major medical journals in pre-specified period of 
time and investigate to what extent survival curves do converge and cross each other. 
Specifically, the objectives of our study were: 
 To explore how frequent survival curves do converge and/or cross; 
 To explore determinants of survival curves convergence and crossing. 
In doing so, we hypothesised the followings: 
 Convergences and crossings are rare phenomenon in medical research 
 Convergence and crossing will be explained by disease type, exposure type, sample 
size, member of comparator groups, number of pairwise comparisons, type of study 
design, length of follow-up time, and type of endpoint. 
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3 Methods and Materials 
We based our research on the following five major peer-reviewed medical journals: 
Annals of Internal Medicine (AIM), British Medical Journal (BMJ), The Journal of the 
American Medical Association (JAMA), The New England Journal of Medicine (NEJM), 
and The Lancet. For each journal we browsed through all 2007 issues and identified all 
publications that included survival graphs.   
3.1 Inclusion and exclusion of publications 
Among the publications with survival graphs, we excluded the following: 1) 
publications with a survival graph having no comparator group (survival graph with a single 
curve), and 2) publications with a survival graph that were reproduced from other journals 
without complete information on methods and results.  
3.2 Study sample and Data extraction 
We identified 177 publications which met our study criteria.  In the process of data 
extraction we observed the following patterns: 
1. Publications with no comparator group (a survival graph with a single curve)    
(Figure 5).     
 
 
Figure 5. A survival graph with out a comparator group. Adapted from the Cancer Gide webpage 
(http://www.cancerguide.org) 
2. Publications with a single endpoint, with two comparator groups presented by a 
single survival graph (Figure 6). For such types of survival graphs there is only a 
single possible pairwise comparison.    
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Figure 6. A survival graph with two comparator groups. Adapted from the Cancer Gide webpage 
(http://www.cancerguide.org) 
3. Publications with a single endpoint but with more than two comparator groups 
presented by a single survival graph (Figure 7). For such types of survival graphs the 
potential pairwise comparison varies depending on the number of comparator groups 
(i.e. survival curves).   
 
Figure 7. A survival graph with more than two comparative curves. Adapted from the Cancer Gide webpage 
(http://www.cancerguide.org) 
In our example, we have potentially six pairwise comparisons [(A vs. B), (A vs. C), 
(A vs. D), (B vs. C), (B vs. D), (C vs. D)].   
4. Publications with multiple endpoints and two comparator groups for each endpoint. 
Here, usually the number of pairwise comparison is equal to the number of endpoints 
(Figure 8).  
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Figure 8. Multiple end points each represented by a single survival graph. Adapted from Veld et al (2007).    
5. Publications with multiple endpoints and more than two comparator groups presented 
by multiple survival graphs (Figure 9). The potential number of pairwise comparison 
may be very large depending on the number of endpoint and the number comparator 
groups.  
 
Figure 9. Multiple endpoint with more than two comparative curves presented by more than one survival 
graphs.Adapted from Marson et al (2007). 
 17 
As some of the publications were included more than one survival graphs, the total 
number of survival graphs observed was greater than the number of publications included in 
the study. We used the followings rules when extracting the data:  
 If death or a combination of death and other outcomes were a primary or secondary 
endpoint, data from this graph was recorded.  
 In case both the primary endpoint was a non-death outcome or a combination of non-
death outcome, we chose a graph representing a combined endpoint, if available; 
otherwise, every graph was recorded. With these criteria some publications were 
represented by one graph, but some were represented by two or more graphs. The 
following data were extracted from each of the 177 identified publications:  
 Type of disease, 
 Type of exposure,  
 Number of comparator groups,  
 Number of pairwise comparison,  
 Type of primary and secondary endpoints,  
 Sample size,  
 Maximum follow-up time,  
 Number of survival curve convergences,  
 Number of survival curve crossings,  
 Type of epidemiologic study design,  
 Result of log-rank test (if reported),  
 Country in which the study was undertaken. 
Survival curve convergences and crossings data were extracted directly from survival curves 
while the remaining data were extracted from the manuscript of the publications.  
3.3 Data Analysis 
  We broadly classified publications as shown in Table 2. The data were analyzed by 
means of contingency tables and simple descriptive statistic. Determinants of convergences 
and crossings were analyzed with logistic regression (Tables 8 & 9). The dependent variables 
convergence and crossing were dichotomized into convergence (=1)/no convergence (=0) and 
crossing (=1)/no crossing (=0) and defined as follows: for Survival curve convergence; (=0) 
represent none of the survival curves in a give publication were converged, and (=1) represent 
at least two survival curves were converged once. For survival curve crossings; (=0) represent 
none of the survival curves in a given publication were crossed while (=1) represent at least 
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two curves were crossed once. The following predictor variables were used and categorized as 
follows: 
 Disease type: cancer (=0), cardiovascular diseases(=1), infections (=2) and all others 
(=3); 
 Exposure type: pharmaceuticals (=0), surgery (=1), diagnostic (=2), procedures and 
devices (=3), and all others(=4); 
 Number of comparator groups1: two comparator groups (=0) and more than two 
comparator groups (=1).  
 Number of pairwise comparison2:  one pairwise comparison (=0) and two or more 
pairwise comparisons (=1).   
 Primary endpoint: death (=0) and non-death outcome (=1).    
 Secondary endpoint: non-death (=0) and death from any cause (=1).    
 Type of study design: randomized controlled trail (RCT) (=0), cohort study (=1) and 
all other (=2).       
 Length of follow-up: 0-180 days (=0), 181-366 days (=1), 367-732 days (=2), 733-
1830 (=3) and more than 1830 days (=4) of follow-up.    
 Sample size: It was expressed per 100 units.  
For independent variable all categories represented by (= 0) used as a reference. For all 
analyses, a 2-tailed P<.05 was considered statistically significant. Data were analyzed in 
SPSS version 16.0.  
 
                                                 
1
 Comparator groups: are two or more groups of patients randomized and exposed to different exposure types in 
a given trial. 
2
 Pairwise comparison: is the number of comparison made between groups.  Usually it is the function of the 
number of comparator groups in a given study and follows the following pattern;  
Number of comparator 2 3 4 5 6 
Potential number of pairwise comparison 1 2 6 10 15 
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4.  Results 
4.1 Descriptive statistics  
We identified a total of 177 publications which met our inclusion criteria, 17 from 
AIM, 7 from BMJ, 44 from JAMA, 68 from NEJM, and 41 from The Lancet. The proportion 
of publications by geographic region varied from 5% for Africa to 39% for Multi-national 
(Table 1). 
Table 1. Publications according to medical journal and Geographic region 
 Geographic region   
Journal America Europe Asia & Australia Africa Multi-national Total (%) 
AIM 7 5 1 0 4 17 (9.6) 
BMJ 1 5 1 0 0 7 (4.0) 
JAMA 22 7 1 2 12 44 (24.9) 
NEMJ 13 9 6 2 38 68(38.4) 
The LANCET 1 14 6 5 15 41 (23.2) 
Total (%) 44 (24.9) 40 (22.6) 15 (8.5) 9 (5.0) 69 (39.0) 177 (100) 
 
Variations in proportion of publications were observed across various study characteristics 
(Table 2). For disease type, the proportion of publications varied from 2% for pulmonary to 
35% for cardiovascular. For type of intervention, the proportion of publications varied from 
5% for „risk factor‟ to 56% for pharmaceutical. For number of comparator groups, the 
proportion varied from 28% for „more than two groups‟ to 72% for publications with „only 
two groups.‟  For number of pairwise comparisons, the proportion of publications ranged 
from 39% for „one pairwise‟ comparison to 61% for „more than one pairwise‟ comparisons.  
For primary endpoint, the proportion of publications ranged from 2% for „other‟ to 37% for 
„single non-death outcome‟. For secondary endpoint, the proportion ranged from 19% for 
„death from any cause‟ to 81% for „non-death outcome.‟ For study design, the range was from 
11% for „other‟ to 68 % for randomized controlled trial (RCT). For length of follow-up time, 
the proportion of publications ranged from 11% for „181-366‟ days of follow-up to 28% for 
„more than 1830‟ days of follow-up. 50% of the publications reported Log-rank test. 
 20 
 
Table 2.  Publications according to study  characteristics 
Variables and Categories  N % 
Disease type  177 100 
 Cancer  47 27 
 Cardiovascular disease 62 35 
 Infection  20 11 
 Kidney disease 11 6 
 Pulmonary disease 4 2 
 Other  33 19 
Exposure type  177 100 
 Pharmaceutical 99 56 
 Surgery  13 7 
 Diagnostic method 14 8 
 Procedure/Device 34 19 
 Risk Factor 8 5 
 Other  9 5 
Number of comparator groups 177 100 
 Two Groups 128 72 
 >Two Groups 49 28 
Number of pairwise  comparison  177 100 
 One Pairwise  69 39 
 >One Pairwise  108 61 
Primary endpoint 177 100 
 Death from any cause 56 32 
 Death + non-death outcome 34 19 
 Single Non-death Outcome 66 37 
 Combined  Non-death Outcome 18 10 
 Other 3 2 
Secondary endpoint 177 100 
 Non-Death Outcome 143 81 
 Death from any  Cause 34 19 
Study type  177 100 
 Randomized controlled trial (RCT) 121 68 
 Cohort Study 36 20 
 Other  20 11 
Length of follow-up (in days) 177 100 
 0-180  34 19 
 181-366  19 11 
 367-732  20 11 
 733-1830  54 31 
 >1830  50 28 
Log-rank value  177 100 
 Not Reported 89 50 
 Reported 88 50 
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Out of the total 177 publications, 138 (78%) had survival curve convergences and 74 
(42%) had survival curve crossings. Variations in the proportion of survival curve 
convergences and crossings were observed across medical journals and geographic regions 
(Table 3). Survival curve convergences ranged from 68% for JAMA to 88% for AIM, and 
from 61% for America to 89% for Africa. The corresponding variations in proportion for 
survival curve crossings were 36% for JAMA to 57% for BMJ, and 37% for Europe to 56% 
for Africa. 
Table 3. Survival curve convergences and crossings by types of journal and geographic region 
   Survival Curve 
   Crossings Convergences 
Type of Journal N % % 
 AIM 17 53 88 
 BMJ 7 57 71 
 JAMA 44 36 68 
 NEMJ 68 40 81 
 The LANCET 41 44 80 
 Total 177 42 78 
Geographic Region N % % 
 America 44 41 61 
 Europe 40 37 83 
 Asia & Australia 15 40 67 
 Africa 9 56 89 
 Multi-national 69 44 87 
 Total 177 42 78 
 
Some variations in survival curve convergences and crossings were observed across 
disease type (Table 4).  The lowest proportion of survival curve convergence was observed 
for pulmonary disease (75%) while the highest proportion was for kidney diseases (91%). For 
survival curve crossings, the lowest proportion was observed for kidney (27%) while the 
highest was for pulmonary (75%).  
 
Table 4. Survival curve convergences and crossings according to disease type 
    Crossings Convergences 
Disease Type  N % %  
 Cancer  47 38 77  
 Cardiovascular 62 39 77  
 Infection 20 55 80  
 Kidney Disease 11 27 91  
 Pulmonary  Disease 4 75 75  
 Other  33 45 76  
 Total  177 42 78  
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Survival curve convergences and crossing by the types of exposure illustrated that the 
lowest proportion of convergence was observed for „risk factor‟ (50%) while the highest 
proportion was observed for the intervention type „other‟ (89%) (Table 5). For survival curve 
crossings the lowest proportion was observed for „risk factor‟ (13%) while the highest 
proportion was observed for pharmaceuticals (48%).  
Table 5  Survival curve convergences and crossings according to exposure type 
    Crossings Convergences 
Exposure Type N % %  
 Pharmaceutical 99 48 83  
 Surgery 13 39 85  
 Diagnostic 14 29 57  
 Procedure/Device 34 38 74  
 Risk factor 8 13 50  
 Other  9 44 89  
 Total  177 42 78  
 
Survival curve convergences and crossings differed across types of primary endpoint 
(Table 6). The lowest proportion was observed for „combined non-death primary outcome‟ 
(67%) while the highest proportion was for „other‟ (100%). The corresponding lowest and 
highest proportions for survival curve crossing were 0% and 56% for „other‟ and „combined 
non-death outcome‟ respectively.  For secondary endpoint, the proportion of convergences 
ranged from 73% for „non-death outcomes‟ to 97% for „death outcome‟. However, no major 
variation was observed for crossing 38% for „death outcome‟ to 43% for „non-death 
outcome‟. 
Table 6.  Survival curve convergences and crossings according to primary end-point 
    Crossings Convergences 
Primary end-point N % %  
 Death from any cause 56 36 75  
 Death + non-death outcome 34 47 94  
 Single non-death outcome 66 42 74  
 Combined non-death outcome 18 56 67  
 Other  3 0 100  
 Total  177 42 78  
 
Survival curve convergences and crossings also differed across length of follow-up 
time (Table 7). The lowest proportion of survival curve convergences was observed for „181-
366‟ days of follow-up (64%) while the highest was observed for „0-180‟ days of follow-up 
(85%). The corresponding figure for survival curve crossing was 26% and 53% for „180-366‟ 
and „0-180‟ days of follow-up respectively.  
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Table 7. Survival curve convergences and crossings according to length of follow-up time 
    Crossings Convergences 
Length of follow-up (in days) N % %  
 0-180 (up to six months) 34 53 85  
 180-366 (up to a year) 19 26 64  
 367-732   (up to two years) 20 40 80  
 733-1830 (up to five years) 54 42 80  
 
> 1830  ( more than five 
years) 50 40 74  
 Total  177 42 78  
 
Variations in survival curve convergences and crossings were observed across the 
number of comparator groups, the number of pairwise comparisons, and the type of 
epidemiological study design. The proportion of survival curve convergences was about the 
same for publications with „more than two groups (76%)‟ and for publications with „only two 
groups (79%).‟ Survival curve crossings ranged from 33% for publications with „more than 
two groups‟ to 45% for publications with „only two groups.‟ For the number of pairwise 
comparisons, survival curve convergences ranged from 71% for publications with „only one 
pairwise comparison‟ to 82% for publications with „two or more pairwise comparisons.‟ The 
proportions of survival curve crossings was almost the same for publications with „only one 
pairwise comparison‟ (41%) to publications with „more than one pairwise comparison (43%).‟  
The proportion of convergences varied from 6% for the study design „other‟ to 84% for 
randomized controlled trial (RCT). Crossings varied slightly from 35% for „other‟ to 44% for 
randomized controlled trial (RCT). 
4.2 Regression analysis 
In bivariate analysis of survival curve convergences we found the following 
statistically significant predictors: „diagnostic‟ versus ‘pharmaceuticals exposure‟ (OR 0.28, 
95% CI 0.09- 0.90), „non-death‟ versus „death‟ as a secondary endpoint (OR 11.9, 95% CI 
1.58-90.37), „cohort‟ versus „RCT‟ study design (OR 0.37, 95% CI 0.16-0.87), „others‟ versus 
„RCT‟ study design (OR 0.28, 95% CI 0.10-0.78) (Table 8). However, no significant 
association was found between convergences and disease type, other categories of exposure 
type, number of comparators group, number of pairwise comparisons, type of primary 
endpoint, length of follow-up time, and sample size. No association was found between 
survival curve crossings and any of the predictor variables.  
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In multivariate analysis of survival curve convergences we found the following 
statistically significant predictors: „two or more pairwise‟versus„only one pairwise 
comparisons‟ (OR 3.7,   95% CI 1.3-10.8), „non-death‟ versus „death‟ as a secondary outcome 
(OR 8.1, 95% CI 1.1-65.5) (Table 9). However, no statistically significant association was 
found between convergences and disease type, exposure type, number of comparators group, 
type of primary endpoint, length of follow-up time, study design, and sample size. No 
association was found between survival curve crossings and any of the explanatory variables.  
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Table 8. Bivariate Analysis of Survival Curve Crossings and Convergences 
 
    95% CI for Odd-ratio 
(OR) 
  
 Crossings as dependent 
variable 
 Convergences as dependent variable 
Independent Variables OR Lower Upper P OR Lower Upper P 
Disease Type         
Cancer (ref.) 1    1    
Cardiovascular .99 .45 2.15 .95 .978 .40 2.38 .96 
Infection 1.96 .68 5.67 .21 1.222 .34 1.43 .76 
All others 1.30 .57 2.96 .53 1.290 .48 3.48 .62 
Exposure Type         
Pharmaceuticals (ref.) 1    1    
Surgery .69 .21 2.26 .54 1.140 .231 5.62 .87 
Diagnostic .44 .13 1.51 .19 .276* .09 .90 .03 
Procedure/device .68 .31 1.52 .35 .576 .23 1.45 .24 
All Others .46 .15 1.41 .17 .498 .16 1.60 .24 
Comparator Groups         
Two groups (ref.) 1    1    
Two or more groups .58 .29 1.17 .12 .824 .38 1.79 .63 
Pairwise comparison         
One pairwise (ref.) 1    1    
Two or more pairwise 1.08 .59 2.01 .79 1.912 .93 3.92 .08 
Primary endpoint         
Death (ref.) 1    1    
Non-death Outcome 1.16 .64 2.12 .62 .602 .29 1.24 .18 
Secondary endpoint         
Non-death (ref.) 1    1    
Death from any cause .83 .39 1.79 .63 11.943* 1.58 90.37 .02 
Study Type         
RTC (ref.) 1    1    
Cohort .81 .38 1.75 .60 .373* .16 .87 .02 
Others .96 .26 1.85 .46 .279* .10 .78 .01 
Follow-ups in Days         
0-180 (ref.) 1    1    
181-366 .31 .09 1.08 .06 .374 .10 1.45 .15 
367-732 .59 .19 1.28 .36 .690 .16 2.93 .62 
733-1830 .65 .28 1.56 .34 .674 .21 2.14 .50 
>1830 .59 .25 1.42 .24 .491 .16 1.53 .22 
Sample size         
Sample Size/100 patient 1.00 .99 1.00 .71 1.00 .99 1.00 .13 
* = significant at < 0.05, ref. = reference variable, OR = Odd ratio, RTC = randomized controlled trial 
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Table 9. Multivariate  Analysis of Survival Curve Crossings and Convergences 
                                                                                         95% CI for odd-ratio (OR)  
 Crossing as dependent 
variable 
  Convergence as dependent 
variable 
Independent Variables OR Lower Lower P OR Lower Upper P 
Disease Type         
Cancer (ref.) 1    1    
Cardiovascular .97 .40 2.32 .94 1.24 .39 3.93 .71 
Infection 1.56 .44 5.54 .48 1.54 .30 7.74 .60 
All others 1.24 .47 3.28 .65 1.94 .53 7.09 .31 
Exposure Type         
Pharmaceuticals (ref.) 1    1    
Surgery .73 .20 2.70 .64 1.15 .18 7.10 .86 
Diagnostic .44 .10 1.86 .27 .50 .10 2.35 .38 
Procedure/device .75 .32 1.78 .52 .82 .28 2.39 .73 
All Others .45 .13 1.59 .22 .90 .22 3.76 .90 
Comparator Groups         
Two groups (ref.) 1    1    
Two or more groups .46 .19 1.00 .07 .54 .17 1.64 .27 
Pairwise comparison         
One pairwise (ref.) 1    1    
Two or more pairwise 1.60 .74 3.43 .22 3.70* 1.26 10.80 .02 
Primary endpoint         
Death (ref.) 1    1    
Non-death Outcome .99 .51 1.92 .98 .49 .21 1.15 .10 
Secondary endpoint         
Non-death (ref.) 1    1    
Death from any cause .71 .30 1.70 .45 8.11 * 1.00 65.48 .05 
Study Types         
RCT (ref.) 1    1    
Cohort 1.19 .43 3.26 .73 .43 .12 1.45 .17 
Others .93 .29 2.88 .90 .32 .09 1.17 .08 
Follow-ups in Days         
0-180 (ref.) 1    1    
181-366 .33 .10 1.36 .13 .44 .10 2.00 .29 
367-732 .57 .16 1.98 .38 .65 .13 3.36 .62 
733-1830 .70 .26 1.86 .47 .59 .16 2.22 .44 
>1830 .76 .25 2.28 .63 .76 .18 3.23 .72 
Sample size         
Sample size/ 100 patient 1.00 .99 1.00 .84 1.00 .99 1.00 .41 
* = significant at < 0.05, ref. = reference variable, OR = Odd ratio, RTC = randomized controlled trial 
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4. Discussion and conclusion 
Our research demonstrated that in major medical journals, survival curve 
convergences were present in almost 8 out of 10 publications and survival curve crossings in 
4 out of 10 publications. Most of these convergences and crossings occurred early in the 
follow-up period.    
Our study has a number of strengths as well as limitations. The main strength of our 
study lies in using the data from five major peer reviewed medical journals for one full year. 
The five journals are among the most prestigious medical journals and likely to present as 
good research as other medical journals.  One of the main limitations lies in the lack of patient 
level data. Our study was exclusively based on published survival curves rather than original 
data. As a result we were unable to estimate directly the variations in relative hazards that lied 
behind the survival curves. We rather used survival curve convergences and crossings as an 
indication that the relative hazard varied over time in survival analysis. Another limitation lies 
in data inaccuracies because we used survival graphs rather than tables and numbers. In 
several publications it was difficult to ascertain whether convergence and crossings occurred 
or not. We observed a number of cases where two or more survival curves seemingly 
converge and cross each other throughout the follow-up period to the point that it was not 
identifiable. The problem was more complicated in survival graphs having more than two 
comparator groups. Another limitation lies in diversity of publications across the study 
characteristics. Too much variation means relatively fewer cases per category, which in turn 
affects the power of the statistical tests of significance. Some of the proportions in our 
contingency tables were overstated due to lower number of cases.    
The findings of this study suggest that convergences and crossings are common 
phenomena in medical research. The result that was similar to the study conducted by Suciu et 
al in Balakrihana and Rao (eds.) 2004, where 55 (43%) out of the 127 publications they 
reviewed involved survival curve crossings. We found that the likelihood of survival curve 
convergences were twice that of survival curve crossings and most of this convergences 
occurred in the first six months of the follow-up period. We do not know why survival curves 
convergences were more common than survival curve crossings but we assume that the reason 
is survival curve crossing can not occur without convergences as the first step towards a full 
crossing.  However, it has to be notice that such comparison was not considered multiple 
convergences and crossings that may have observed in each survival graph. We were mainly 
interested whether or not convergence and/or crossing involved not how many times. Our 
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research also revealed that convergences and crossings were hugely varied across study 
characteristics although we did not found any particular patterns of variations. While survival 
curve convergence was statistically associated with only a few explanatory variables, survival 
curve crossing was not associated with any of the predictor variables nether in bivariate nor in 
multivariate analysis.  It was difficult to pinpoint exactly why this is the case. We suspect that 
either the numbers of cases in some categories was too small, or factors other than the study 
characteristics were responsible. However, we are well aware that statistical insignificance 
may not always mean that our explanatory variables have no association to the dependent 
variables.  
Our study findings have at least one major implication: vertical effectiveness measures 
may provide results that are not representative of the effectiveness over the relevant life span 
for the patient.   In Meta analysis researchers tends to base their result on counting adverse 
events at the end of trails. This practice is acceptable if the relative hazard is constant 
throughout the trail. Our results, however, indicates that this is frequently not the case even 
when we use such rough measures as survival curve crossings. Presumably, the assumption 
about constant relative hazards is even more frequently violated if we used more sophisticated 
measures. Survival curve convergences and crossings may imply that the difference in 
survival time is nil, grater at some times and lower at other times. If the effectiveness of an 
intervention to be measured only at the end of a trial, we risk losing valuable information that 
can save lives and improves intervention effectiveness. We, therefore, suggest that 
intervention effectiveness measures should be based on repeated measure, or area between the 
curve rather than depending exclusively on a single number generated at one specific time.   
We conclude that survival curve convergences and crossings are common phenomena 
in medical research. The phenomena seem to be only weekly associated with particular study 
characteristics. The result warrants care in making inferences about the effectiveness of 
interventions for chronic diseases on the basis of an estimate at a single point in time.  
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